In the third section of this year’s Generics Bulletin Top 50, a handful of new entrants make their way into the bottom of the rankings, while some volatility is seen among longstanding ranking companies.
After the first part of this year’s Generics Bulletin Top 50 showed upheaval among the top 10 leading off-patent companies and the second part demonstrated movement among the mid-table players (see sidebar), this third and final section of the ranking sees a handful of new entrants making their way into the bottom of the chart, while others exit altogether.
Leading off the third table, we see India’s Biocon climbing from 35th to 31st position in our ranking, ahead of...
This article compiles all of the data from Generics Bulletin’s 2025 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.
In the third instalment of this year’s Generics Bulletin Top 50, we reveal which firms have entered the ranking for the first time.
In the second instalment of Generics Bulletin’s Top 50 ranking for 2025, we see plenty of movement among our mid-table collection of companies.
Two leading German generics and biosimilars giants were the big movers in our top ten ranking of off-patent industry leaders for 2025. We reveal the latest developments among the top players in the first instalment of this year’s Generics Bulletin Top 50.
Multiple strengths of sitagliptin saw average price increases that topped our rundown of UK generic pricing data in June.
As multiple molecules experienced triple-digit percentage price rises in May, pioglitazone once again led the way after already topping our table of price increases in April.
Diabetes medication pioglitazone topped the list of the fastest-rising UK generics prices in April, according to market researcher WaveData.
